Rigel Pharmaceuticals (RIGL) Finished Goods (2018 - 2026)

Rigel Pharmaceuticals' Finished Goods history runs 9 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• In Q1 2026, Finished Goods rose 9.05% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $4.1 million (up 9.05% YoY), while the FY2025 annual figure was $4.7 million, down 6.02% from the prior year.
• Finished Goods was $4.1 million for Q1 2026 at Rigel Pharmaceuticals, down from $4.7 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $5.8 million in Q3 2024 to a low of $1.1 million in Q2 2022.
• Historically, Finished Goods has averaged $2.8 million across 5 years, with a median of $2.0 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Finished Goods jumped 232.49% in 2024, then slumped 69.37% in 2025.
• A 5-year view of Finished Goods shows it stood at $1.9 million in 2022, then dropped by 20.8% to $1.5 million in 2023, then surged by 232.49% to $5.0 million in 2024, then slipped by 6.02% to $4.7 million in 2025, then dropped by 13.05% to $4.1 million in 2026.
• The last three Finished Goods figures came in at $4.1 million (Q1 2026), $4.7 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.